Sepehr Rokhsar

Hematology | Oncology
9090 Wilshire Blvd Ste 300
Beverly Hills, CA 90211

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2 publications

A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer.

A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer.

Journal: EBioMedicine
Published: December 06, 2018

Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas.

Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas.

Journal: Leukemia research
Published: January 08, 2015
Showing 1-2 of 2

Last Updated: 09/26/2026